Skip to main content
TipRanks
Go Ultimate75% OFF

Bio-Path Holdings (BPTH) Q3 2024 Earnings Report

485 Followers

BPTH Q3 2024 EPS Results

Actual EPS
-$0.70
Consensus EPS
-$1.02
Beat/Miss
Beat by +$0.32
One Year Ago EPS
-$6.40

BPTH Q3 2024 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2024
Date
11/15/2024
Time
Before Open
Conference Call
Friday, November 15, 2024

Q3 2024 Earnings Call Audio

BPTH Q3 2024 Earnings Call
0:00 / 0:00

Q3 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2024 Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 15, 2024|% Change Since:-99.97%|
Earnings Call Sentiment|Positive

The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.

Company Guidance

In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.

  • Expansion of DNAbilize PlatformInitiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
  • Progress in Cancer Treatment TrialsContinued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.
  • Publication and Potential of BP1003Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.
  • Financial ImprovementsNet loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.
  • Rapid Enrollment in Clinical TrialsFaster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.

BPTH Earnings History

BPTH earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Nov 12, 20262026 (Q3)―--0.11―
Aug 18, 20262026 (Q2)―-0.09-0.5584.09% (+0.47)
May 08, 20262026 (Q1)―-0.03-0.492.75% (+0.37)
Mar 20, 20262025 (Q4)―-0.032.62-101.03% (-2.65)
Nov 14, 20252025 (Q3)-0.40-0.11-0.783.71% (+0.59)
Aug 19, 20252025 (Q2)-0.40-0.55-1.1652.33% (+0.61)
May 29, 20252025 (Q1)-0.38-0.40-4.8891.80% (+4.48)
Mar 28, 20252024 (Q4)-0.372.62-3.43176.38% (+6.05)
Nov 15, 20242024 (Q3)-1.02-0.70-6.489.06% (+5.70)
Aug 15, 20242024 (Q2)-1.54-1.16-10.689.06% (+9.44)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed